摘要
为降低虚高药价、避免过度医疗、斩断医药行业的腐败链条,我国自2018年开始试行药品"4+7"带量采购政策。这一政策的出台引发行业巨震:中标药品价格大幅下降,药品市场重新洗牌,中小型药企举步维艰,大规模创新型药企释放政策红利。对此,提出新政背景下医药企业转型发展的应对建议。
In order to reduce the high drug prices,avoid excessive medical treatment,and cut off the corrupt chain of the pharmaceutical industry,China began to trial the drug"4+7"procurement policy in 2018. The introduction of this policy triggered a huge earthquake in the industry: the price of the winning drug was drastically reduced,the pharmaceutical market was reshuffled,the small and medium-sized pharmaceutical companies were struggling,and the large-scale innovative pharmaceutical companies released the policy dividend. In this regard,this paper puts forward suggestions for the transformation and development of pharmaceutical enterprises under the background of the new policy.
作者
谈在祥
范舜
TAN Zai-xiang;FAN Shun(Xuzhou Medical University,Xuzhou Jiangsu 221006,China)
基金
江苏省第六批教育改革发展战略性与政策研究重点课题(ZLZC2017-13)
关键词
药品采购
带量集中采购
以价换量
医药企业
procurement of medicines
centralized procurement with quantity
price-for-money
pharmaceutical companies
